Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Priority Review “Vouchers” Offered To Firms Developing HIV Drugs In FDA Bill

Executive Summary

The Senate's version of FDA user fee reauthorization legislation includes a provision designed to encourage creation of products that treat HIV and other diseases affecting developing countries

You may also be interested in...



NIH Public/Private Partner Grants Highlighted At BIO/Gates Forum

The National Institute of Health's initiative to provide grants to public/private partnerships for early-stage research marks one of several collaborative efforts to advance tropical disease and HIV compounds, NIAID Director Anthony Fauci said March 12

NIH Public/Private Partner Grants Highlighted At BIO/Gates Forum

The National Institute of Health's initiative to provide grants to public/private partnerships for early-stage research marks one of several collaborative efforts to advance tropical disease and HIV compounds, NIAID Director Anthony Fauci said March 12

Wyeth, GSK Vaccines May Get Sales Boost Under Pilot For Developing Countries

Pediatric pneumococcal vaccines in development by Wyeth and GlaxoSmithKline could be the first products to benefit from a pilot program designed to create an incentive to develop vaccines that treat the diseases of the developing world

Related Content

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel